☰

Jamie B. Spangler - Publications

Affiliations: 
2011-2017 Stanford University, Palo Alto, CA 
 2017- Chemical & Biomolecular Engineering Johns Hopkins University, Baltimore, MD 
Tree Info Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Huang B, Abedi M, Ahn G, Coventry B, Sappington I, Tang C, Wang R, Schlichthaerle T, Zhang JZ, Wang Y, Goreshnik I, Chiu CW, Chazin-Gray A, Chan S, Gerben S, ... ... Spangler JB, et al. Designed endocytosis-inducing proteins degrade targets and amplify signals. Nature. PMID 39322662 DOI: 10.1038/s41586-024-07948-2  0.346
2024 Leonard EK, Tomala J, Gould JR, Leff MI, Lin JX, Li P, Porter MJ, Johansen ER, Thompson L, Cao SD, Hou S, Henclova T, Huliciak M, Sargunas PR, Fabilane CS, ... ... Spangler JB, et al. Engineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activity. Jci Insight. PMID 39115939 DOI: 10.1172/jci.insight.173469  0.468
2024 Berger S, Seeger F, Yu TY, Aydin M, Yang H, Rosenblum D, Guenin-Macé L, Glassman C, Arguinchona L, Sniezek C, Blackstone A, Carter L, Ravichandran R, Ahlrichs M, Murphy M, ... ... Spangler JB, et al. Preclinical proof of principle for orally delivered Th17 antagonist miniproteins. Cell. PMID 38936360 DOI: 10.1016/j.cell.2024.05.052  0.596
2024 Ray CMP, Yang H, Spangler JB, Mac Gabhann F. Mechanistic computational modeling of monospecific and bispecific antibodies targeting interleukin-6/8 receptors. Plos Computational Biology. 20: e1012157. PMID 38848446 DOI: 10.1371/journal.pcbi.1012157  0.519
2024 Fabilane CS, Stephenson AC, Leonard EK, VanDyke D, Spangler JB. Cytokine/Antibody Fusion Protein Design and Evaluation. Current Protocols. 4: e1061. PMID 38775006 DOI: 10.1002/cpz1.1061  0.427
2024 Tomala J, Cao SD, Spangler JB. Engineering Anticytokine Antibodies for Immune Modulation. Journal of Immunology (Baltimore, Md. : 1950). 212: 225-234. PMID 38166248 DOI: 10.4049/jimmunol.2300467  0.377
2023 Ray CM, Yang H, Spangler JB, Mac Gabhann F. Mechanistic computational modeling of monospecific and bispecific antibodies targeting interleukin-6/8 receptors. Biorxiv : the Preprint Server For Biology. PMID 38187701 DOI: 10.1101/2023.12.18.570445  0.519
2023 Tomasovic LM, Liu K, VanDyke D, Fabilane CS, Spangler JB. Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. PMID 37999893 DOI: 10.1007/s40259-023-00635-0  0.523
2023 Silver AB, Tzeng SY, Lager M, Wang J, Ishihara J, Green JJ, Spangler JB. An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2. Cell Reports. Medicine. 4: 101289. PMID 37992685 DOI: 10.1016/j.xcrm.2023.101289  0.355
2023 Kishimoto TK, Fournier M, Michaud A, Rizzo G, Roy C, Capela T, Nukolova N, Li N, Doyle L, Fu FN, VanDyke D, Traber PG, Spangler JB, Leung SS, Ilyinskii PO. Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease. Journal of Autoimmunity. 140: 103125. PMID 37844543 DOI: 10.1016/j.jaut.2023.103125  0.47
2023 Sun H, Lee HS, Kim SH, Fernandes de Lima M, Gingras AR, Du Q, McLaughlin W, Ablack J, Lopez-Ramirez MA, Lagarrigue F, Fan Z, Chang JT, VanDyke D, Spangler JB, Ginsberg MH. IL-2 can signal via chemokine receptors to promote regulatory T cells' suppressive function. Cell Reports. 42: 112996. PMID 37598341 DOI: 10.1016/j.celrep.2023.112996  0.542
2023 Bernstein ZJ, Shenoy A, Chen A, Heller NM, Spangler JB. Engineering the IL-4/IL-13 axis for targeted immune modulation. Immunological Reviews. PMID 37283511 DOI: 10.1111/imr.13230  0.524
2023 Leonard EK, Tomala J, Gould JR, Leff MI, Lin JX, Li P, Porter MJ, Johansen ER, Thompson L, Cao SD, Henclova T, Huliciak M, Vaněk O, Kovar M, Leonard WJ, ... Spangler JB, et al. Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity. Biorxiv : the Preprint Server For Biology. PMID 37205604 DOI: 10.1101/2023.05.03.539272  0.483
2023 Deckers J, Anbergen T, Hokke AM, de Dreu A, Schrijver DP, de Bruin K, Toner YC, Beldman TJ, Spangler JB, de Greef TFA, Grisoni F, van der Meel R, Joosten LAB, Merkx M, Netea MG, et al. Engineering cytokine therapeutics. Nature Reviews Bioengineering. 1: 286-303. PMID 37064653 DOI: 10.1038/s44222-023-00030-y  0.308
2023 Yang H, Ulge UY, Quijano-Rubio A, Bernstein ZJ, Maestas DR, Chun JH, Wang W, Lin JX, Jude KM, Singh S, Orcutt-Jahns BT, Li P, Mou J, Chung L, Kuo YH, ... ... Spangler JB, et al. Design of cell-type-specific hyperstable IL-4 mimetics via modular de novo scaffolds. Nature Chemical Biology. PMID 37024727 DOI: 10.1038/s41589-023-01313-6  0.649
2022 Yang H, Karl MN, Wang W, Starich B, Tan H, Kiemen A, Pucsek AB, Kuo YH, Russo GC, Pan T, Jaffee EM, Fertig EJ, Wirtz D, Spangler JB. Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 35841152 DOI: 10.1016/j.ymthe.2022.07.008  0.409
2021 Bernstein ZJ, Spangler JB. Insights into the anticancer mechanisms of interleukin-15 from engineered cytokine therapies. The Journal of Clinical Investigation. 131. PMID 34596048 DOI: 10.1172/JCI152857  0.516
2021 Glassman CR, Mathiharan YK, Jude KM, Su L, Panova O, Lupardus PJ, Spangler JB, Ely LK, Thomas C, Skiniotis G, Garcia KC. Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. Cell. 184: 983-999.e24. PMID 33606986 DOI: 10.1016/j.cell.2021.01.018  0.635
2020 VanDyke D, Wang W, Spangler JB. Innovative synthetic signaling technologies for immunotherapy Current Opinion in Biomedical Engineering. 16: 1-8. DOI: 10.1016/J.Cobme.2020.05.007  0.39
2019 Yang H, Kureshi R, Spangler JB. Structural Basis for Signaling Through Shared Common γ Chain Cytokines. Advances in Experimental Medicine and Biology. 1172: 1-19. PMID 31628649 DOI: 10.1007/978-981-13-9367-9_1  0.477
2019 Spangler JB, Moraga I, Jude KM, Savvides CS, Garcia KC. A strategy for the selection of monovalent antibodies that span protein dimer interfaces. The Journal of Biological Chemistry. PMID 31387945 DOI: 10.1074/Jbc.Ra119.009213  0.593
2019 Leonard EK, Leff MI, Spangler JB. Weaponizing T-cell receptors through molecular engineering. The Journal of Biological Chemistry. 294: 5805-5806. PMID 30979848 DOI: 10.1074/Jbc.H119.008479  0.38
2019 Krohl PJ, Ludwig SD, Spangler JB. Emerging technologies in protein interface engineering for biomedical applications. Current Opinion in Biotechnology. 60: 82-88. PMID 30802788 DOI: 10.1016/J.Copbio.2019.01.017  0.343
2019 Silva DA, Yu S, Ulge UY, Spangler JB, Jude KM, Labão-Almeida C, Ali LR, Quijano-Rubio A, Ruterbusch M, Leung I, Biary T, Crowley SJ, Marcos E, Walkey CD, Weitzner BD, et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 565: 186-191. PMID 30626941 DOI: 10.2210/Pdb6Dg5/Pdb  0.654
2018 Spangler JB, Trotta E, Tomala J, Peck A, Young TA, Savvides CS, Silveria S, Votavova P, Salafsky J, Pande VS, Kovar M, Bluestone JA, Garcia KC. Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy. Journal of Immunology (Baltimore, Md. : 1950). PMID 30104245 DOI: 10.4049/Jimmunol.1800578  0.662
2018 Kureshi R, Bahri M, Spangler JB. Reprogramming immune proteins as therapeutics using molecular engineering Current Opinion in Chemical Engineering. 19: 27-34. DOI: 10.1016/J.Coche.2017.12.003  0.375
2017 Moraga I, Spangler JB, Mendoza JL, Gakovic M, Wehrman TS, Krutzik P, Garcia KC. Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers. Elife. 6. PMID 28498099 DOI: 10.7554/Elife.22882  0.739
2017 Moraga I, Spangler JB, Mendoza JL, Gakovic M, Wehrman TS, Krutzik P, Garcia KC. Author response: Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers Elife. DOI: 10.7554/Elife.22882.019  0.657
2015 Mitra S, Ring AM, Amarnath S, Spangler JB, Li P, Ju W, Fischer S, Oh J, Spolski R, Weiskopf K, Kohrt H, Foley JE, Rajagopalan S, Long EO, Fowler DH, et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity. 42: 826-38. PMID 25992859 DOI: 10.1016/J.Immuni.2015.04.018  0.735
2015 Spangler JB, Tomala J, Luca VC, Jude KM, Dong S, Ring AM, Votavova P, Pepper M, Kovar M, Garcia KC. Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms. Immunity. 42: 815-25. PMID 25992858 DOI: 10.1016/J.Immuni.2015.04.015  0.719
2015 Spangler JB, Moraga I, Mendoza JL, Garcia KC. Insights into cytokine-receptor interactions from cytokine engineering. Annual Review of Immunology. 33: 139-67. PMID 25493332 DOI: 10.1146/Annurev-Immunol-032713-120211  0.705
2014 Moraga I, Spangler J, Mendoza JL, Garcia KC. Multifarious determinants of cytokine receptor signaling specificity. Advances in Immunology. 121: 1-39. PMID 24388212 DOI: 10.1016/B978-0-12-800100-4.00001-5  0.705
2012 Spangler JB, Manzari MT, Rosalia EK, Chen TF, Wittrup KD. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. Journal of Molecular Biology. 422: 532-44. PMID 22706026 DOI: 10.1016/J.Jmb.2012.06.014  0.565
2010 Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proceedings of the National Academy of Sciences of the United States of America. 107: 13252-7. PMID 20616078 DOI: 10.1073/Pnas.0913476107  0.596
2007 You M, Spangler J, Li E, Han X, Ghosh P, Hristova K. Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers. Biochemistry. 46: 11039-46. PMID 17845056 DOI: 10.1021/Bi700986N  0.322
Show low-probability matches.